Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

15,800 Drugs Hit by Japan Price Cuts, Pharma Margins Under Pressure

Japan’s FY26 National Health Insurance (NHI) drug price revision has taken effect following analysis by GlobalData released on May 8, 2026. The policy cuts prices across nearly 15,800 medicines by an average of 4.02% and expands the G1 repricing system.
  • News
15,800 Drugs Hit by Japan Price Cuts, Pharma Margins Under Pressure

FDA Leadership Shakeup Raises Concerns, Over Drug Approval Stability

A senior leadership change is unfolding inside the U.S. Food and Drug Administration as Tracy Beth Hoeg, acting head of the agency’s drug evaluation center, is expected to leave after the resignation of FDA Commissioner Marty Makary in Washington, according
  • News
FDA Leadership Shakeup Raises Concerns, Over Drug Approval Stability

Process Deviations in Pharma for GMP Compliance in 2026: Root Cause Analysis, Investigation, and CAPA Guide

Process deviations in GMP environments require structured investigation, accurate documentation, and effective CAPA closure. This article explains how quality teams strengthen deviation management, improve data integrity compliance, and reduce FDA inspection risks through risk-based control strategies and systematic lifecycle handling.
  • Blog, Quality Management System
GMP audit trail deviation control workflow showing quality specialists analyzing deviation reports, CAPA records, and data integrity documentation in a regulated pharmaceutical environment.

FDA Warning Letter to Simtra Exposes Sterile Contamination Risks, GMP Failures Raise Compliance Concerns

The U.S. Food and Drug Administration issued a warning letter to Simtra Biopharma Solutions after an inspection revealed significant contamination-related GMP violations at its sterile manufacturing facility in Halle, Germany. Inspectors identified repeated microbial recoveries, aseptic processing failures, and weak
  • News
FDA Warning Letter to Simtra Exposes Sterile Contamination Risks, GMP Failures Raise Compliance Concerns

FDA Expands Drug Repurposing Initiative, Approved Drugs Reenter AI-Driven Regulatory Evaluation Pathways

The U.S. Food and Drug Administration launches a new drug repurposing initiative to address unmet medical needs in chronic and rare diseases. The agency invites public input on approved medicines that may support new indications using existing scientific evidence. Additionally,
  • News
FDA Expands Drug Repurposing Initiative, Approved Drugs Reenter AI-Driven Regulatory Evaluation Pathways

Are You Ready for FDA Compliance Changes in 2026 — AI Is Transforming Inspections and Supply Chains?

At INTERPHEX 2026 in New York, George Kwiecinski, CEO and co-founder of Global Key Solutions Corp, discussed how AI reshapes FDA regulatory compliance and GMP inspection strategy in an interview with PharmTech. He explained that limited inspection capacity, evolving QMSR
  • News
Are You Ready for FDA Compliance Changes in 2026 — AI Is Transforming Inspections and Supply Chains?

Train Validation Test Failures in GMP Inspections in 2026

This article explains how train validation test failures impact GMP inspection outcomes, focusing on data validation strategy GMP, audit trail control, and validation dataset design GMP. It highlights how weak validation logic increases compliance and data integrity risks in regulated
  • Blog, Validation and Qualification
Pharmaceutical laboratory showing model validation GMP workflow with focus on data validation strategy GMP, audit trail data validation, and risk based validation GMP ensuring compliance and traceability.

FDA GMP Crackdown Hits 3 Countries in One Sweep — Hidden Quality Failures Exposed

FDA escalates enforcement in 2026 and exposes major GMP failures across India, China, and the US. The agency identifies repeated breakdowns in OOS investigations, data integrity controls, and quality oversight systems. At the same time, FDA also challenges Intas Pharmaceuticals,
  • News
FDA GMP Crackdown Hits 3 Countries in One Sweep — Hidden Quality Failures Exposed